[go: up one dir, main page]

EP1347769A2 - Effet preventif contre le cancer de morinda citrifolia - Google Patents

Effet preventif contre le cancer de morinda citrifolia

Info

Publication number
EP1347769A2
EP1347769A2 EP01992025A EP01992025A EP1347769A2 EP 1347769 A2 EP1347769 A2 EP 1347769A2 EP 01992025 A EP01992025 A EP 01992025A EP 01992025 A EP01992025 A EP 01992025A EP 1347769 A2 EP1347769 A2 EP 1347769A2
Authority
EP
European Patent Office
Prior art keywords
dietary supplement
fruit
recited
juice
dmba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01992025A
Other languages
German (de)
English (en)
Other versions
EP1347769A4 (fr
Inventor
Chen Xing Su
Claud Jarakae Jensen
Stephen P. Story
Mian-Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tahitian Noni International Inc
Original Assignee
Morinda Inc
Tahitian Noni International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/997,588 external-priority patent/US20020068102A1/en
Application filed by Morinda Inc, Tahitian Noni International Inc filed Critical Morinda Inc
Publication of EP1347769A2 publication Critical patent/EP1347769A2/fr
Publication of EP1347769A4 publication Critical patent/EP1347769A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to inhibiting cancer.
  • the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
  • free radicals Natural cell processes exist within the human body that use oxygen and produce toxins that are commonly referred to as "free radicals.” These free radicals may be highly reactive oxidizing substances that attach to and attack carbohydrates, deoxyribonucleic acid ("DNA”), enzymes, fats, and/or proteins within the body. The free radicals typically interfere with cellular function and reproduction, and may cause dysfunction and/or death of cells, tissues, and organs within the body. While a natural defense mechanism exists to reduce the cellular damage caused by the free radicals, the defense mechanism may become increasingly inefficient as the body ages. As such, damage caused by the free radicals has been implicated in several age-associated diseases, such as Alzheimer's disease, cancer, diabetes, heart disease, macular degeneration, and Parkinson's disease. In fact, suggestions have even been made that the damage caused by the free radicals may be an integral factor in the aging process of the human body.
  • age-associated diseases such as Alzheimer's disease, cancer, diabetes, heart disease, macular degeneration, and Parkinson's disease. In fact,
  • the amount of free radicals produced within the body is typically increased as the individual is exposed to cigarette smoke or various other toxins, such as mercury. Furthermore, the production of the free radicals is typically enhanced by exercise, since exercise instigates a need for oxygen within the body.
  • Vitamin C Ascorbic acid
  • Another technique used to reduce the cellular damage includes the regular consumption of biofavonoids, such as a mixture of catechins, phenolic acid, proan, and thocyanidins.
  • biofavonoids such as a mixture of catechins, phenolic acid, proan, and thocyanidins.
  • One such mixture is made from a highly bioactive substance called proanthocyanidins, obtained from the bark of the Maritime Pine in France and is the active ingredient in a product known as Pycnogenol ® .
  • this mixture of biofavonoids may be absorbed in the skin and retained for as long as 72 hours to neutralize free radicals. It may improve circulation and may strengthen the immune system.
  • Another technique used to reduce cellular damage includes the consumption of grape seed extract, which has been said to strengthen and protect living tissues.
  • grape seed extract may strengthen blood vessels, improve the skin, and aid circulation. Furthermore, grape seed extract may be advantageous in defeating the hormone dihydrotesterone ("DHT"), which prevents the hair follicle growth cycle, thereby stimulating healthy hair growth.
  • DHT hormone dihydrotesterone
  • reports have claimed that various substances may be used to reduce cellular damage caused by the free radicals, contradictory results have been obtained that cause researchers to continue searching for answers. Accordingly, it would be an improvement in the art to augment or even replace the substances currently used with other substances to inhibit interference with cellular function and reproduction, thereby inhibiting cellular dysfunction.
  • the present invention relates to inhibiting cancer.
  • the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
  • Implementation of the present invention takes place in association with a dietary supplement that is processed from the fruit of the Indian Mulberry plant, scientifically known as Morinda citrifolia L.
  • the dietary supplement includes reconstituted Morinda citrifolia fruit juice from pure juice puree of French Polynesia.
  • the supplement may also include other natural juices, such as a natural grape juice concentrate, a natural blueberry juice concentrate, and/or another natural juice concentrate.
  • the dietary supplement is not processed from dried or powdered Morinda citrifolia, rather liquid is extracted from the fruit of the Morinda citrifolia and used to create the dietary supplement.
  • Titian Noni ® One implementation of the dietary supplement is referred to as "Tahitian Noni ® " and may be obtained from Morinda, Inc., which has a principal place of business located at 5152 N. Edgewood Dr. #100, Provo, UT, 84604.
  • Use of the dietary supplements described herein include scavenging lipid hydroperoxides and superoxide anion free radicals within the body, thereby reducing cellular damage in the human body and/or providing a cancer preventative effect at the initiation stage of carcinogenesis.
  • the dietary supplements include a combination of compounds that work at the cellular level to increase the positive functionality of cells in the body, including cell regeneration and cell function.
  • the combination of compounds increases the ability of cells within the body to absorb and utilize nutrients such as vitamins and minerals, and stimulates the production of T-cells within the immune system.
  • the T-cells are a type of lymphocyte or white blood cell that lead the attack against infections within the body, end the immune response, and or kill cancer cells and/or cells infected with a virus. Results from experiments described herein indicate that prevention of carcinogen-DNA adduct formation and the scavenging performed in accordance with the present invention contribute to cancer inhibition.
  • one ounce of the dietary supplement is consumed per day to reduce toxins produced by natural cell processes with in the human body.
  • consumption amounts may include more than one ounce per day or less than one ounce per day.
  • the dietary supplement may be taken in the morning and/or before meals.
  • the present invention relates to reducing inhibiting cancer.
  • the present invention relates to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
  • the following disclosure of the present invention is grouped into three subheadings, namely "Dietary Supplement,” “Reducing Cellular Damage,” and “Inhibiting Cancer.”
  • the utilization of the subheadings is for convenience of the reader only and is not to be construed as limiting in any sense.
  • Dietary Supplement Embodiments of the present invention take place in association with a dietary supplement that is processed from the fruit of the Indian Mulberry plant, scientifically known as Morinda citrifolia L.
  • the plant is an evergreen tree or shrub that is typically found in open tropical coastal regions, such as in Asia, Australia, and in islands of the Pacific Ocean. It is a member of the coffee family and typically grows in open lowlands, often on or along lava flows, and at edges of forests.
  • the straight trunk, large, green, elliptical leaves, white tubular flowers, and ovoid, yellow fruit readily identify the Morinda citrifolia.
  • the plant may be cultivated in gardens and has been naturalized in both moist and dry areas from sea level to about 1,300 feet above sea level.
  • the Morinda citrifolia flourishes in the lush and unspoiled lands of French Polynesia, which includes Tahiti, and grows particularly large and lush in French Polynesia because of the ideal climate and soil conditions, and because the islands are generally still in their pristine condition.
  • a mature plant may reach heights of 15 to 20 feet tall and may bear fruit throughout the year.
  • the Morinda citrifolia typically includes coarse branches that are angular in cross section. The branches are thick and may be conspicuously marked with leaf scars. The leaves are ovate, thick, deeply veined, short-stemmed, green, and shiny, and may grow to lengths of over eight inches.
  • Small white flowers of the Morinda citrifolia are born on globose, fused heads to form an inflorescence that is typically about an inch in diameter. While each of the heads produces many flower buds, typically only one or two of the buds open on a particular head during a given period of time.
  • the flowers typically include five to seven lobed corollas that are often about one-third of an inch long in size.
  • the flowers are closely packed and appear in various stages of development on the head. For example, green buds may be present near the apex of a particular head, while older flowers near the base of the head may have already opened and closed. Before the last flower near the apex of a head has bloomed, small yellowish-green fruitlets replace the flowers.
  • the fruit of the Morinda citrifolia When the fruit of the Morinda citrifolia is mature, it is typically several inches long. Generally, the fruit is elongate in shape and includes a warty appearance that is caused by being marked with the polygonal outlines of the uneven individual fruitlet growth patterns. A pit, left as a scar from the corolla, is located within each of the polygonal outlines. If picked green, the fruit typically rots. As such, it is typically advantageous to allow the fruit to mature and ripen prior to picking.
  • the skin Once the fruit of the Morinda citrifolia has matured, the skin is typically a whitish color and the flesh is a whitish-yellow color.
  • the mature fruit is generally the size of a potato and resembles a small breadfruit.
  • the seeds or kernels of the fruit are generally triangular in shape and are reddish-brown in color.
  • An air sac, attached to one end of a seed, allows a detached seed to be buoyant.
  • the Morinda citrifolia is rich in natural ingredients.
  • the natural ingredients include: (from the leaves) alanine, anthraquinones, arginine, ascorbic acid, aspartic acid, calcium, beta-carotene, cysteine, cystine, glycine, glutamic acid, glycosides, histidine, iron, leucine, isoleucine, methionine, niacin, phenylalanine, phosphorus, proline, resins, riboflavin, serine, beta-sitosterol, thiamine, threonine, tryptophan, tyrosine, ursolic acid, and valine; (from the flowers) acacetin-7-o-beta-d(+)-glucopyranoside, 5,7-dimethyl- apigenin-4'-o-beta-d(+)- galactopyranoside, and 6,8-dimethoxy-3-methylanthraquino
  • the fruit of the Morinda citrifolia includes health-enhancing enzymes that, for example, aid in easing inflammation, calming feelings of anxiety, supporting weight management, and promoting circulatory health in humans.
  • the Morinda citrifolia is an adaptogenic herb that supports balanced body systems by responding to the body's need for stimulation or relaxation.
  • Embodiments of the present invention relate to the creation and utilization of a dietary supplement that includes fruit juice from Morinda citrifolia.
  • the dietary supplement includes reconstituted Morinda citrifolia fruit juice from pure juice puree of French Polynesia.
  • the supplement may also include other natural juices, such as a natural grape juice concentrate, a natural blueberry juice concentrate, and/or another natural juice concentrate.
  • the dietary supplement is not processed from dried or powdered Morinda citrifolia, rather liquid is extracted from the fruit of the Morinda citrifolia and used to create the dietary supplement, as will be discussed below.
  • the dietary supplement is referred to as "Tahitian Noni ® " and may be obtained from Morinda, Inc., which has a principal place of business located at 5152 N. Edgewood Dr. #100, Provo, UT, 84604.
  • the fruit of the Morinda citrifolia is harvested, either by hand or by mechanical equipment, when it is at least one inch long and up to 12 inches in diameter. At this time, the fruit generally has a color ranging from a dark green through a yellow-green up to a white color, and gradations of color in between. The fruit is thoroughly cleaned after being harvested and before being processed.
  • the fruit is allowed to ripen or age from 0 to 14 days by being placed on equipment so that the ripening fruit is prevented from contacting the ground.
  • the fruit is typically covered with a cloth or netting material during aging, but can be aged without being covered.
  • the fruit is light in color, such as a light green, a light yellow, a white, or a translucent color.
  • the fruit is inspected for spoilage and/or for excessively green color and hard firmness. Spoiled and hard green fruit is separated from the acceptable aged fruit.
  • the acceptable aged fruit is typically placed in plastic lined containers for further processing and transport. While the containers of fruit may be held from 0 to 30 days, most containers are generally held for 7 to 14 days before processing.
  • the containers can optionally be stored under refrigerated conditions prior to further processing.
  • the fruit is unpacked from the storage containers and is processed through a manual or mechanical separator.
  • the seeds and peel are separated from the juice and pulp.
  • the juice and pulp may be packaged into containers for storage and transport.
  • the containers may be stored in refrigerated, frozen, or room temperature conditions.
  • the juice may be immediately processed into a finished juice product.
  • Filtering equipment may be used to remove pulp from the juice.
  • the filtering equipment may include a centrifuge decanter, a screen filter with a size from 1 micron up to 2000 microns (in one embodiment it is more preferably less than 500 microns), a filter press, reverse osmosis filtration, and/or any other standard commercial filtration devices.
  • the operating filter pressure may range from 0.1 psig up to about 1000 psig.
  • the flow rate may range from 0.1 g.p.m. up to 1000 g.p.m., and in one embodiment more preferably between 5 and 50 g.p.m.
  • the wet pulp may be washed and filtered at least once to remove any juice from the pulp.
  • the wet pulp typically has a fiber content of 10 to 40 percent by weight and may be pasteurized at a minimum temperature of 181°F (83°C) and then packed in drums for further processing or made into a high fiber product.
  • the Morinda citrifolia juice and puree are typically blended in a homogenous blend, after which they are mixed with other ingredients, such as flavorings, sweeteners, nutritional ingredients, botanicals, extracts, and/or colorings.
  • flavorings may include, but are not limited to, artificial and/or natural flavor or ingredients that contribute to palatability.
  • sweeteners include, but are not limited to, natural sugars derived from corn, sugar beet, sugar cane, potato, tapioca, or other starch-containing sources that are chemically or enzymatically converted to crystalline chunks, powders, and/or syrups, or other sweeteners, including artificial or high intensity sweeteners, some of which are aspartame, sucralose, stevia, saccharin, etc.
  • nutritional ingredients include vitamins (e.g., A, Bl through B12, C, D, E, Folic Acid, Pantothenic Acid, Biotin, etc.), minerals and/or trace elements (e.g., calcium, chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese, molybdenum, potassium, iodine, zinc, and/or phosphorus), herbs and/or botanical extracts (e.g., alfalfa grass, bee pollen, chlorella powder, Dong Quai powder, Ecchinacea root, Gingko Biloba extract, Horsetail herb, Shitake mushroom, spirulina seaweed, and/or grape seed extract), bioactive chemicals (e.g., caffeine, ephedrine, L-carnitine, creatine, and or lycopene), and/or compounds.
  • vitamins e.g., A, Bl through B12, C, D, E, Folic Acid, Pantothenic Acid, Bio
  • the finished juice product is typically heated and pasteurized at a minimum temperature of 181°F (83°C) or higher, such as up to 212°F (100°C).
  • the product is filled and sealed into a final container of plastic, glass, or another suitable material that withstands the processing temperatures.
  • the containers are maintained at the filling temperature or may be cooled rapidly and then placed in a shipping container.
  • the shipping containers are typically wrapped with a material and in a manner to maintain or control the temperature of the product in the final containers.
  • embodiments of the present invention relate to reducing cellular damage in the human body.
  • the free radicals are chemical species that possess an unpaired electron and are highly reactive oxidizing substances that attach to and attack carbohydrates, deoxyribonucleic acid ("DNA”), enzymes, fats, and/or proteins within the body.
  • the free radicals are produced continuously in cells either as accidental by-products of metabolism or deliberately during, for example, phagocytosis.
  • the free radicals typically interfere with cellular function and reproduction, and may cause dysfunction and/or death of cells, tissues and organs within the body.
  • the amount of free radicals produced within the body is typically increased as the individual is exposed to cigarette smoke or various other toxins, such as mercury. Furthermore, the production of free radicals is typically enhanced by exercise, since exercise instigates a need for oxygen within the body. Excessive production of free radical-mediated oxidative alteration of fatty acids, also known as lipid peroxidation, leads to damage of cellular structure, enzymes, and/or tissues. Reactions occur in the body to form hydrogen peroxide and the highly toxic hydroxyl radical. A superoxide anion is converted to a hydroxyl radical and interacts with nitric oxide to form peroxinitrite, which degrades to form a hydroxyl radical.
  • Peroxy radicals typically remove hydrogen from lipids, such as polyunsaturated fatty acids, resulting in a formation of lipid hydroperoxides and further propagate radical pathways by regeneration of alkyl radicals. Hydroperoxides have direct toxic effects for endothelial cells and degrade to form the hydroxyl radical. Hydroperoxides also form stable aldehydes, such as malondialdehyde (MDA), which damage membranes by facilitating the formation of protein cross-links and other end products.
  • MDA malondialdehyde
  • Hydroperoxyeicosatetraenoic acids HPETEs
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • PLC protein kinase C
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • HTETEs Hydroperoxyeicosatetraenoic acids
  • a series of free radical catalyzed peroxidation products of arachidonic acid, called isoprostanes, is formed in a cyclo-oxygenase-independent manner and remains associated with membrane phospholipids until released by phospholipases.
  • Defense mechanisms are critically important for the ultimate effect of oxidative stress and free radicals on cells and tissues within the body. Such defense mechanisms typically interrupt lipid peroxidation and inorganic free radical reaction or scavenge the reactive intermediates formed.
  • the dietary supplement described herein is used to scavenge lipid hydroperoxides and superoxide anion free radicals within the body, thereby reducing cellular damage in the human body.
  • the dietary supplement includes a combination of compounds that work at the cellular level to increase the positive functionality of cells in the body, including cell regeneration and cell function.
  • the combination of compounds increases the ability of cells within the body to absorb and utilize nutrients such as vitamins and minerals.
  • the combination has also stimulated the production of T-cells within the immune system.
  • the T-cells are a type of lymphocyte or white blood cell that lead the attack against infections within the body, end the immune response, and/or kill cancer cells and/or cells infected with a virus.
  • one fluid ounce (30 mL) of the dietary supplement is consumed per day to reduce toxins produced by natural cell processes with in the human body.
  • other embodiments include the consumption of more than one fluid ounce per day or less than one fluid ounce per day.
  • the dietary supplement is taken in the morning and/or before meals when the stomach is typically empty.
  • Tahitian Noni provides a stronger effect to scavenge superoxide anion free radicals within the body than the regular intake of vitamin C, pycnogenol ® (maritime pine bark extract), or grape seed powder.
  • Tahitian Noni ® may be used as a dietary supplement to scavenge lipid hydroperoxides and superoxide anion free radicals within the body. Examples of such experiments conducted and results achieved are more fully described in United States Provisional Patent Application Serial No.
  • a dietary supplement having juice from the Morinda citrifolia may be used to scavenge lipid hydroperoxides and/or superoxide anion free radicals.
  • a daily intake of Tahitian Noni ® has a stronger effect to scavenge superoxide anion free radicals than Vitamin C, Pycnogenol, ® (maritime pine bark extract), or grape seed powder.
  • Tahitian Noni ® may be consumed together with Vitamin C, Pycnogenol, ® (maritime pine bark extract), and/or grape seed powder to scavenge lipid hydroperoxides and/or superoxide anion free radical.
  • the utilization of the dietary supplement, such as Tahitian Noni, ® in accordance with the present invention allows an individual to escape or at least delay the onset of inherited diseases and age-associated declines in vision, hearing, and memory loss and other age-associated physiological declines.
  • embodiments of the present invention relate to inhibiting cancer.
  • embodiments of the present invention relate to the use of a dietary supplement that provides a cancer preventative effect at the initiation stage of carcinogenesis.
  • various components include terpene compounds, anthraquinones, morindone, morindin, asperuloside, acubin, caproic acid, caprylic acid, damnacanthal, scopoletin, polysaccharide, and alkaloids.
  • regular consumption of a dietary supplement that includes juice form the Morinda citrifolia provides a cancer preventive effect at the initiation stage of chemical carcinogenesis by preventing the carcinogen-DNA adduct formation.
  • DMBA 7, 12-dimethylbenza anthrancine
  • LPO lipid hydroperoxide quenching activity of the dietary supplement was examined in vitro by LPO assay.
  • LPO oxidized leucomethylene blue to methylene blue in the presence of hemoglobin. The resultant blue color is quantified spectrophotometrically (660 nm).
  • Authentic cumene hydroperoxide was used as a standard to monitor the LPO quenching activity of the dietary supplement.
  • the superoxide anion radical (“SAR”) scavenging activity of the dietary supplement was examined in vitro by tetrazolium nitroblue (“TNB”) assay. SAR reduced TNB into formazan blue, which absorbed at 602 nm.
  • a SAR scavenger reduced the absorbence by reacting with SAR.
  • phenazine methosulfate was used as a catalyst.
  • the activity of the dietary supplement was compared to that of three known antioxidants against SAR in vitro at the recommended daily dose per serving by U.S. RDAs (U.S. Government Recommended Daily Allowances) or by manufacturers.
  • Sixty mg of Vitamin C obtained from Roche Vitamins Inc. Parsippany, NJ
  • 60 mg of Pycnogenol® obtained from Twin Laboratories Inc., Ronkonkoma, New York 11779
  • 100 mg of grape seed powder obtained from DNP International Co., Inc.
  • DNA adduct formation was reduced in female SD rats drinking 10% of the dietary supplement. Furthermore, the levels of DMBA-DNA adducts were reduced by 30% in the heart, 41% in the lungs, 42% in the liver, and 80% in the kidneys. Even more dramatic results were obtained in male C57 BL-6 mice. Ten percent of the dietary supplement was able to prevent DMBA-DNA adduct formation by 60% in the heart,
  • Typical profiles of DMBA-DNA adducts in control liver (A) and lung (C) of female SD rats were induced.
  • the densities and the numbers of DNA adducts in liver (B) and lung (D) were reduced in 10% of the dietary supplement group.
  • the level of DMBA adducts was prevented by 42% in the liver, 41% in the lung, when compared to the control group
  • the films were exposed at -80 ⁇ C for three hours
  • Typical profiles of DMBA-DNA adducts in control heart (A) and kidney (C) of female SD rats were induced.
  • the densities and the numbers of DNA adducts in heart (B) and kidney (D) were reduced in 10% dietary supplement group
  • the level of DMBA adducts was prevented by 30% in the heart, 80% in the kidney, when compared to the control group.
  • the films were exposed at -80 D C for three hours.
  • the activity of the dietary supplement was observed inn vitro.
  • a dose- dependent curve of the SAR scavenging activity of the dietary supplement in vitro was obtained by TNB assay (see below).
  • a dose-dependent curve of the LPO quenching activity of the dietary supplement in vitro was also observed by LPO assay (see also below).
  • the SAR scavenging activity of the dietary supplement was compared to that of Vitamin C, grape seed powder (“GSP”), and Pycnogenol® ("PYC”). Under the experimental conditions, the SAR scavenging activity of the dietary supplement was shown to be 2.8 times that of Vitamin C, 1.4 times that of PYC, and 1.1 times that of GSP.
  • the results of the experiment indicate that 10% the dietary supplement reduced the DMBA-DNA adduct formation in different organs of female SD rats and male C57 Bl-6 mice. Adducts particularly reduced the most in the kidneys. Since DNA adduct formation is a step in chemical carcinogenesis, the preventive effect of the dietary supplement on DMBA adduct formation indicates that the use of the dietary supplement prevents cancer at the initiation stage of chemical carcinogenesis.
  • the strong activities of the dietary supplement against SAR and LPO were observed in vitro by TNB and LPO assays. Since the dietary supplement showed higher activity, it provides that the dietary supplement protects cells or lipids form oxidative modification mediated by SAR. Both the carcinogen-DNA adduct prevention and the antioxidant properties contribute to the cancer preventive effect of the dietary supplement in accordance with the present invention.
  • the mechanism by which the dietary supplement prevents the formation of DMBA-DNA adducts is as follows:
  • the dietary supplement inhibits phase I enzyme activity while enhancing phase II enzyme and DNA repair enzyme activities.
  • the dietary supplement blocks the redox-cycling between the carcinogen and their metabolites by interrupting the metabolic pathway, scavenging oxygen free radicals, and quenching the consequent LPO.
  • the dietary supplement also affects redox- sensitive signal transduction pathways and alters gene expression. Therefore, the interactions of carcinogens, oxygen free radicals, and LPO are changed by the dietary supplement.
  • a dietary supplement in accordance with the present invention provides a cancer preventive effect at the initiation stage of chemical carcinogenesis.
  • a dietary supplement in accordance with the present invention inhibits cancer and other diseases, while maintaining overall good health.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un supplément diététique et son utilisation pour inhiber le cancer et/ou pour obtenir un effet préventif contre le cancer au cours de l'étape initiale de la carcinogenèse. Ce supplément diététique renferme un jus de fruit reconstitué à base de Morinda citrifolia obtenu à partir de purée de jus pure de la Polynésie française, et peut renfermer d'autres jus naturels, tels qu'un concentré de jus de raisin naturel, un concentré de jus de bleuet naturel et/ou un autre concentré de jus naturel. Ce supplément diététique permet de réduire la formation d'adduits DMBA-ADN dans plusieurs organes, tels que le coeur, les reins, les poumons et le foie. La formation d'adduits à base d'ADN favorise la carcinogenèse chimique. L'utilisation de ce supplément diététique permet de protéger les cellules et/ou les lipides contre toute modification oxydante induite par SAR (radical superoxyde anionique). A ce titre, l'utilisation de ce supplément diététique contribue à l'inhibition du cancer.
EP01992025A 2000-12-05 2001-12-05 Effet preventif contre le cancer de morinda citrifolia Withdrawn EP1347769A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25141700P 2000-12-05 2000-12-05
US251417P 2000-12-05
US09/997,588 US20020068102A1 (en) 2000-12-01 2001-11-29 Reducing cellular damage in the human body
PCT/US2001/046835 WO2002045654A2 (fr) 2000-12-05 2001-12-05 Effet preventif contre le cancer de morinda citrifolia

Publications (2)

Publication Number Publication Date
EP1347769A2 true EP1347769A2 (fr) 2003-10-01
EP1347769A4 EP1347769A4 (fr) 2008-02-20

Family

ID=26941594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01992025A Withdrawn EP1347769A4 (fr) 2000-12-05 2001-12-05 Effet preventif contre le cancer de morinda citrifolia

Country Status (4)

Country Link
EP (1) EP1347769A4 (fr)
JP (1) JP2004529077A (fr)
AU (1) AU2002232504A1 (fr)
WO (1) WO2002045654A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254913B1 (en) * 1999-08-27 2001-07-03 Morinda, Inc. Morinda citrifolia dietary fiber and method
US8790727B2 (en) 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US7244463B2 (en) 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
EP1389124A4 (fr) * 2001-04-17 2004-12-15 Morinda Inc Effets palliatifs du jus et de l'huile de i morinda citrifolia /i
US7442395B2 (en) 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US20050037101A1 (en) * 2003-08-12 2005-02-17 Mian-Ying Wang Preventative effects of morinda citrifolia on mammary breast cancer
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
KR101915726B1 (ko) * 2017-03-08 2018-11-06 한국교통대학교 산학협력단 항암 활성을 갖는 식품 첨가제 조성물, 김치 양념 조성물 및 항암 기능성 김치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288491A (en) * 1992-09-24 1994-02-22 Herbert Moniz Noni (Morinda Citrifolia) as a pharmaceutical product
EP0897264A4 (fr) * 1996-04-22 1999-09-08 Henkel Corp Composition naturelle antioxydante
FR2783137A1 (fr) * 1998-09-10 2000-03-17 Royal Tahiti Noni Composition a base d'extraits de morinda citrifolia

Also Published As

Publication number Publication date
WO2002045654A2 (fr) 2002-06-13
AU2002232504A1 (en) 2002-06-18
JP2004529077A (ja) 2004-09-24
WO2002045654A9 (fr) 2004-02-12
EP1347769A4 (fr) 2008-02-20
WO2002045654A3 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
US20020068102A1 (en) Reducing cellular damage in the human body
US20050202109A1 (en) Methods and compositions for inhibiting monoamine oxidase and catechol-o-methyltransferase
US20050186296A1 (en) Profiles of lipid proteins and inhibiting HMG-CoA reductase
US20070160700A1 (en) Methods and compositions for reactivating acetylcholinesterase
US20070166416A1 (en) Formulations and Methods for Preventing and Treating Substance Abuse and Addiction
US20050202108A1 (en) Methods and compositions for inhibiting angiotensin converting and chymase enzymes
EP1771187A2 (fr) Compositions d'extraits de feuilles de morinda citrifolia et procedes de preparation associes
AU2004291030A1 (en) Preventative effects of morinda citrifolia on mammary breast cancer
WO2006050012A2 (fr) Compositions a base de morinda citrifolia et methode pour inhiber une xanthine oxydase
EP1347769A2 (fr) Effet preventif contre le cancer de morinda citrifolia
US20060280818A1 (en) Nicotinic acetylcholine receptor antagonist
US20080206376A1 (en) Methods and compositions for inhibiting angiotensin converting and chymase enzymes
US20090022828A1 (en) Methods and compositions for inhibiting angiotensin converting and chymase enzymes
JP2007016015A (ja) ヒストン脱アセチル化酵素および腫瘍壊死因子変換酵素阻害
US8025910B2 (en) Method and composition for administering bioactive compounds derived from Morinda citrifolia
US20100034905A1 (en) Method of treating burns
US8535741B2 (en) Method and composition for administering bioactive compounds derived from Morinda citrifolia
EP1962878A2 (fr) Formulation et procedes d'utilisation d'huile de graines de morinda citrifolia
EP1968619A2 (fr) Formulations antivirales a base de morinda citrifolia l. et methodes d'administration
US20090196944A1 (en) Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
WO2005120538A1 (fr) Formulation a base de morinda citrifolia de 5-lox et de 15-lox
WO2007064547A2 (fr) Formulation a base de morinda citrifolia et methodes de gestion du poids
JP2007314461A (ja) ニコチン性アセチルコリン受容体アンタゴニスト

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17D Deferred search report published (corrected)

Effective date: 20020906

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAHITIAN NONI INTERNATIONAL, INC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WANG, MIAN-YING

Inventor name: STORY, STEPHEN, P.

Inventor name: JENSEN, CLAUD, JARAKAE

Inventor name: SU, CHEN, XING

A4 Supplementary search report drawn up and despatched

Effective date: 20080123

17Q First examination report despatched

Effective date: 20080704

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701